

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/094828 A1

(51) International Patent Classification⁷: **C07D 477/20**,
477/06

(21) International Application Number: PCT/IB02/01670

(22) International Filing Date: 15 May 2002 (15.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
594/DEL/01 18 May 2001 (18.05.2001) IN

(71) Applicant (for all designated States except US): **RAN-
BAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru
Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KUMAR, Yatendra**
[IN/IN]; U-26/5, Phase - III, DLF Qutab Enclave, Gurgaon
122001, Haryana (IN). **TEWARI, Neera** [IN/IN]; K10/19
(First Floor), Phase - II, DLF Qutab Enclave, Gurgaon
122001, Haryana (IN). **RAI, Bishwa, Prakash** [IN/IN];
Jagdish Pur, Sohauly, Azamgarh 276306, Uttar Pradesh
(IN).

(74) Common Representative: **RANBAXY LABORATO-
RIES LIMITED**; Deshmukh, Jayadeep R., 600 College
Road East, Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF IMIPENEM

(57) Abstract: The present invention relates to an improved, cost effective and industrially advantageous process for the preparation of imipenem.



WO 02/094828 A1


PROCESS FOR THE PREPARATION OF IMIPENEM

FIELD OF THE INVENTION

The present invention relates to an improved, cost effective and industrially advantageous process for the preparation of imipenem.

BACKGROUND OF THE INVENTION

Imipenem monohydrate of Formula I which is the N-formimidoyl derivative of thienamycin and has the structural Formula I.




FORMULA I

It is the first clinically available member of a new class of β -lactam antibiotics that possess the carbapenem ring system. Imipenem exhibits an extremely broad spectrum of activity against gram-positive and gram-negative aerobic and anaerobic species, which is partly due to its high stability in the presence of β -lactamases.

Imipenem was first disclosed in U.S. Patent No. 4,194,047. Several general methods for the preparation of N-methylene derivatives of thienamycin including imipenem have been outlined in U.S. Patent No. 4,194,047 starting from thienamycin. The process for the preparation of imipenem has been found to give the product in low yield and of poor quality due to inherent instability of the starting compound i.e. thienamycin.

U.S. Patent No. 4,292,436 provides an alternate method for the preparation of imipenem from bicyclo ketone precursor of Formula II,



FORMULA II

10 wherein R is a protecting group, comprising activating the keto ester and reacting the activated keto ester with N-formimidoyl-2-aminoethanethiol to obtain carboxyl protected imipenem which gives imipenem after hydrogenation. However, the process gives low yields of the final product (59% in solution and 35% of isolated imipenem monohydrate).

15

U.S. Patent No. 4,374,772 gives an improved process for preparing imipenem from dilute aqueous solutions of thienamycin using benzylic formimidate reagents. However, the process has the disadvantage of producing at least 5% of dimer bis-thienamycin formamidene along with the desired product imipenem.

20

U.S. Patent No. 4,894,450 uses new reagents – bis (chloro-substituted phenyl) phosphorochloridate to activate the bicycloketone precursor of formula II, wherein R is a protecting group. Subsequent reaction with cysteamine hydrochloride, amidine formation and hydrogenolysis of the ester group gives good
25 yield of imipenem. However, the reagent employed for activation is not available

commercially and its preparation involves a cumbersome multistage purification process.


In light of the above drawbacks in the prior art processes, there is a need for the development of a process for the preparation of imipenem which is convenient to operate on an industrial scale, employs readily and commercially available raw materials and reagents and which process gives substantially pure product in good yield.

SUMMARY OF THE INVENTION

It is an object of the present invention to solve the problems associated with the prior art and provide an efficient process. The process provides obvious benefits with respect to economics and convenience to operate on a commercial scale.

Accordingly, the present invention relates to an improved process for the preparation of imipenem of sufficient purity and high yield starting from the bicyclo ketone precursor of formula II, wherein R is a protecting group.


In particular, the present invention relates to a process for the preparation of imipenem of Formula I



FORMULA I

comprising:


- a) activating a keto ester compound of Formula II,



FORMULA II

wherein R is a protecting group,


with a phosphorohalidate derivative of Formula VI,



FORMULA VI

wherein X is a halogen atom and R' is aryl,


in the presence of a base and a catalytic amount of a dialkylaminopyridine, to obtain enol phosphate compound of Formula III,



FORMULA III

wherein R and R' have the same meaning as defined above,


- b) reacting the enol phosphate intermediate of Formula III, in situ with 2-aminoethanethiol or an acid addition salt thereof to get thienamycin ester of Formula IV,



FORMULA IV

wherein R has the same meaning as defined above,

- c) reacting thienamycin ester of Formula IV in situ with benzyl formimidate or an acid addition salt thereof in the presence of a base to get carboxyl protected imipenem of Formula V,



FORMULA V

wherein R has the same meaning as defined above, and


- d) hydrogenating the carboxyl protected imipenem of formula V in an aqueous medium to obtain imipenem.

The reactions at steps a) and c) are preformed in the presence of a base which may be a secondary amine or a tertiary amine. Examples of secondary

amines include diisopropylamine, dicyclohexylamine, 2,2,6,6-

tetramethylethylpiperidine (TMP) and 1,1,3,3-tetramethylguanidine (TMG). Examples of suitable tertiary amines include diisopropylethylamine, triethylamine and tributylamine.

5 The presence of a catalytic amount of dialkylaminopyridine at step a) prevents
the formation of impurity of formula VII,



FORMULA VII

The impurity of Formula VII is formed in substantial quantities (14-15% by HPLC) by side reaction of the hydroxymethyl group at the 6-position of the carbapenem.

15

Dialkylaminopyridines are used in catalytic amounts, preferably in the range of about 0.5 to 2% w/w relative to the keto ester of Formula II. For the purpose of the present invention, dialkylaminopyridine includes pyridine substituted at the 2- or 4-position. Examples of such dialkylamino substituents include N,N-dimethylamino, N,N-diethylamino, N,N-dicyclohexylamino, N-cyclohexyl-N-methylamino, 1-pyrrolidinyl, 1-piperidinyl and mixture(s) thereof.

The protecting group R in the compound of Formula II is any carboxylic acid protecting group which may be easily removed by hydrogenation, such as benzyl, p-nitrobenzyl or methoxymethyl.

In the compound of Formula VI, X is a halogen atom which may be chloro, bromo or iodo. Particularly preferred is chloro. R' in the compound of Formula VI is aryl, preferably phenyl, which may be substituted.

5

Compounds of Formula II, VI and benzylformimidate or its acid addition salts may be obtained by methods known in the art.

The reaction at step a) is carried out in an organic solvent such as N, N-dimethyl acetamide (DMAc), N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP), ethylacetate, dichloromethane, tetrahydrofuran, or mixture(s) thereof. Preferably a mixture of dichloromethane and any of the solvents chosen from DMAc, DMF or NMP is used. The reaction at step b) is carried out at a temperature of from about -50 to -75°C, preferably at about -60 to -75°C.

15

Steps a), b) and c) are performed *in situ*, thus the solvent and the base are common to the three steps. Additional amount of the base is added to facilitate the reaction at step c).

20

Acid addition salts of 2-aminoethanethiol and benzylformimidate used at steps b) and c) respectively may be the same or different and may arise from either organic or inorganic acids. Examples of such salts include hydrochloride, hydrobromide, hydroiodide, sulfate, methanesulfonate, benzenesulfonate, fumarate, tartrate, thiocyanate, tosylate, phosphate, picrate, succinate, pivalate, benzoate,

acetate and citrate salts. Particularly preferred are the hydrochloride salts of both 2-aminoethanethiol and benzylformimidate.

The hydrogenation step d) is carried out after suitable aqueous work up of the
5 reaction mixture from step c). Preferably, a lower alcohol is added to the obtained aqueous solution of compound V and hydrogenation carried out at a pH of about 7 to 8 in the presence of N-methylmorpholine buffer. Examples of lower alcohols which may be added include methanol, ethanol, isopropanol and propanol. The hydrogenation may be carried out using any of the metal catalysts such as platinum
10 oxide, platinum / carbon, palladium hydroxide and palladium/carbon.

Imipenem is obtained as a solution after hydrogenation and filtration of the catalyst. Imipenem may then be isolated from the solution in the usual manner by lyophilization and/or crystallization methods known in the art but is preferably
15 crystallized by the method described in the patent application filed concurrently herewith.

DETAILED DESCRIPTION OF THE INVENTION

In the following section one preferred embodiment is described by way of
20 example to illustrate the process of the invention. However, it is not intended in any way to limit the scope of the present invention.

PREPARATION OF IMIPENEM

Example 1

Step a) - Preparation of enol phosphate intermediate

A solution of p-nitrobenzyl (3R, 5R, 6S)-2oxo-6-[(1R)-1-hydroxyethyl]
5 carbapenem-3-carboxylate (30g) was dissolved in a mixture of N, N-
dimethylacetamide (300ml) and dichloromethane (150ml). The solution was cooled
to -55°C and 4-(dimethylamino)pyridine (0.17g) was added followed by
diisopropylethylamine (26.7g). The mixture was stirred for 5 min. at -55°C and then
a solution of diphenylchlorophosphate (25.4g) in dichloromethane (30ml) was added
10 dropwise at -55 to -45°C. The reaction mixture thus obtained was stirred further for
30 minutes to obtain the enol phosphate ester.

Step b) - Preparation of thienamycin ester

The reaction mixture from step a) was further cooled to -70 to -75°C and a
15 solution of 2-aminoethanethiol hydrochloride (12g) in N,N-dimethylacetamide (60ml)
was added in 10 min at -75 to -60°C. The reaction mixture was stirred for another 60
min. to produce p-nitrobenzyl ester of thienamycin.

Step c) - Preparation of p-nitrobenzyl ester of imipenem

20 To the above reaction mixture from step b), was added diisopropylethylamine
(16.0g) and benzyl formimidate hydrochloride (20.0g) at -50 to -55°C. The reaction
mixture was maintained for about one and a half hour at the same temperature. The
temperature was then raised to -20°C in 20-30 min and the reaction mixture stirred
for 20-30 min at this temperature to obtain the imipenem ester.


Step d) - Preparation of imipenem

The above clear solution of step c) was poured into a mixture of water (300ml), isopropanol (150ml) and N-methylmorpholine (26g) maintained at 5-10°C and the pH of the solution adjusted to 7.0 to 7.5. The solution was hydrogenated at 5 3-4 kg pressure for 2.5 hour at 10-25°C over palladium / carbon. The mixture was filtered and assayed for imipenem (80%, as determined by HPLC).

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.


WE CLAIM:

1. A process for the preparation of imipenem of Formula I

**FORMULA I**


comprising :

- a) activating a keto ester compound of Formula II,

**FORMULA II**


wherein R is a protecting group

with a phosphorohalidate of Formula VI

**FORMULA VI**

wherein X is a halogen atom and R' is aryl,


in the presence of a base and a catalytic amount of a dialkylaminopyridine to obtain enolphosphate compound of Formula III,



FORMULA III

wherein R and R' have the same meaning as defined above,


- b) reacting the enol phosphate intermediate of Formula III, in situ with 2-aminoethanethiol or an acid addition salt thereof to get thienamycin ester of Formula IV,



FORMULA IV

wherein R has the same meaning as defined above,

- c) reacting thienamycin ester of Formula IV in situ with benzyl formimidate or an acid addition salt thereof in the presence of a base to get carboxyl protected imipenem of Formula V,



FORMULA V

wherein R has the same meaning as defined above, and

d) hydrogenating the carboxyl protected imipenem of formula V in an aqueous medium to obtain imipenem.

2. The process of claim 1 wherein the dialkylaminopyridine is 4-(dimethylamino)pyridine.
3. The process of claim 1 wherein the base used at step a) and step c) is a secondary amine or a tertiary amine.
4. The process of claim 3 wherein said base is selected from the group consisting of diisopropylamine, dicyclohexylamine, 2,2,6,6-tetramethylethylpiperidine (TMP), 1,1,3,3-tetramethylguanidine(TMG), diisopropylethylamine, triethylamine, tributylamine, and mixture(s) thereof.
5. The process of claim 1 wherein the protecting group R is benzyl, p-nitrobenzyl or methoxymethyl in the compound of Formula II.
6. The process of claim 1 wherein the reaction at step a) is performed in an organic solvent.

7. The process of claim 6 wherein said organic solvent is selected from the group consisting of N,N-dimethylacetamide, N,N-dimethylformamide, N-methylpyrrolidone, ethyl acetate, dichloromethane, tetrahydrofuran, and mixture(s) thereof.
8. The process of claim 6 wherein the reaction at step a) is performed in a mixture of dichloromethane and one of the solvents selected from N,N-dimethylacetamide, N, N-dimethyl formamide and N-methylpyrrolidone.
9. The process of claim 1 wherein the reaction at step b) is performed at a temperature of from about -60 to -75°C.
10. The process of claim 1 wherein R' is phenyl in the compound of Formula III.
11. The process of claim 1 wherein the hydrogenation at step d) is carried out in an aqueous medium comprising a mixture of water and a lower alcohol.
12. The process of claim 11 wherein the lower alcohol is selected from the group consisting of methanol, ethanol, isopropanol, and propanol.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB02/01670

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 477/20; 477/06

US CL : 540/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 540/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 02/36594 A1 (RANBAXY LABORATORIES, LTD) SEE EXAMPLE 1, STEPS 1, 2 AND 3.	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

13 SEPTEMBER 2002

Date of mailing of the international search report

21 OCT 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

USPTO/ MARK L. BERCH/jmr

Telephone No. (703) 308-1935